Status:
COMPLETED
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
6-18 years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Pediatric patients with Type 1 diabetes for at least one year
- HbA1c less than 12%
- Willing to administer at least 3 injections per day
- Willing to perform self monitored blood glucose (SMBG) at least 4 times per day, includes subject and/or parent/guardian, as necessary
Exclusion
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
378 Patients enrolled
Trial Details
Trial ID
NCT00071448
Start Date
June 1 2002
End Date
June 1 2004
Last Update
December 22 2016
Active Locations (76)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35294
2
Novo Nordisk Investigational Site
Mobile, Alabama, United States, 36617
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85013
4
Novo Nordisk Investigational Site
Tucson, Arizona, United States, 85712